Paul Tudor Jones Crinetics Pharmaceuticals, Inc. Transaction History

Tudor Investment Corp Et Al

  • $26.8 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
BUY
$25.62 - $37.07 $173,293 - $250,741
6,764 Added 20.5%
39,764 $1.41 Million
Q3 2023

Nov 15, 2023
BUY
$15.97 - $30.59 $95,372 - $182,683
5,972 Added 22.1%
33,000 $981,000
Q2 2023

Aug 14, 2023
BUY
$15.73 - $23.6 $425,150 - $637,860
27,028 New
27,028 $487,000
Q3 2022

Nov 14, 2022
BUY
$18.11 - $22.37 $484,496 - $598,464
26,753 New
26,753 $525,000

Others Institutions Holding CRNX

# of Institutions
241
Shares Held
79.5M
Call Options Held
23.3K
Put Options Held
44.3K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email